Citigroup
AEGR

Citigroup’s Aegerion Pharmaceuticals AEGR Stock Holding History

Citigroup’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-67,100
Closed -$199K – 7478
2016
Q3 		$199K Buy
67,100
+18,800
+39% +$32.6K ﹤0.01% 4661
2016
Q2 		$72K Buy
48,300
+14,900
+45% +$34.1K ﹤0.01% 5343
2016
Q1 		$124K Sell
33,400
-12,600
-27% -$78K ﹤0.01% 5509
2015
Q4 		$465K Buy
46,000
+43,500
+1,740% +$524K ﹤0.01% 3936
2015
Q3 		$34K Buy
2,500
+1,000
+67% +$17.8K ﹤0.01% 5691
2015
Q2 		$28K Buy
+1,500
New +$32.5K ﹤0.01% 5917

Citigroup's AEGR Position: Q4 2016 in Review

Citigroup sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 58,529 shares — an estimated $174K sold.

Citigroup first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $1.14M in Q4 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Citigroup reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Citigroup sold 58,529 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $174K.
  • Citigroup first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Citigroup's Aegerion Pharmaceuticals position peaked at $1.14M in Q4 2013.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.